Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Eisai’s Dayvigo Accepted for EMA Review
Eisai said on July 16 that the European Medicines Agency (EMA) has accepted for review a marketing authorization application for its orexin receptor antagonist Dayvigo (lemborexant) for the treatment of chronic insomnia in adults.Dayvigo was approved in the US in…
To read the full story
Related Article
- Eisai’s Dayvigo Accepted for UK Regulatory Review
July 3, 2026
BUSINESS
- Boehringer’s Survodutide Makes Mark in Japan PIII Obesity Trial
October 6, 2026
- Kyowa Finds Nitrosamines in 2 Antidepressants; No Recall Planned
October 6, 2026
- Nippon Zoki Bags Japan Rights to Taiwan Firm’s Knee Osteoarthritis Drug
October 6, 2026
- AstraZeneca, Academic Society Join Hands on Obesity Care in Japan
October 6, 2026
- Daiichi Sankyo to Take Sole Charge of Emgality Information Activities
October 6, 2026
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
The development of Boehringer Ingelheim’s survodutide is gathering pace, putting the GLP-1/glucagon receptor agonist in contention to become the next…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…